MW 360.4 Da, Purity >98%. L-type Ca2+ channel blocker. Antihypertensive *in vivo*. Achieve your results faster with highly validated, pure and trusted compounds.
Images
Key facts
- CAS number
- 39562-70-4
- Purity
- > 98%
- Form
- Solid
- Molecular weight
- 360.4 Da
- Molecular formula
- C18H20N2O6
- PubChem identifier
- 4507
- Nature
- Synthetic
Target data
Alternative names
A3AR, A3R, AA3R_HUMAN, ABC member 16, MDR/TAP subfamily, ABC16, ABCB1, ABCBB_HUMAN, AD 026, ADORA 3, AI838772, AIS, ANDR_HUMAN, ANKTM 1, AR, AR JP, AR8, ARA3, ATP binding cassette sub family B (MDR/TAP) member 11, ATP-binding cassette sub-family B member 11, AW493413, Abacavir hypersensitivity, susceptibility to, Adenosine A3 receptor, Adenosine receptor A3, Aland island eye disease (Forsius Eriksson ocular albinism, ocular albinism type 2), Androgen nuclear receptor variant 2, Androgen receptor, Androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease), Ankyrin-like with transmembrane domains protein 1, BRIC2, BXR, Beta-interferon, Bile salt export pump, Bsep, CAC1C_HUMAN, CAC1D_HUMAN, CAC1F_HUMAN, CAC1S_HUMAN, CACH 2, CACH1, CACH3, CACN 2, CACN1, CACN4, CACNA 1D, CACNAF, CACNAF1, CACNL1A1, CACNL1A2, CACNL1A3, CCHL1A1, CCHL1A2, CCHL1A3, CDCD2, CMD1E, CMPD2, COD 3, CORDX, CORDX 3, CSNB2A, CSNBX 2, CaV1.2, Cach1b, Calcium channel, Calcium channel L type alpha 1 polypeptide isoform 1 cardiac muscle, Calcium channel L type alpha 1 polypeptide isoform 2, Calcium channel cardic dihydropyridine sensitive alpha 1 subunit, Calcium channel neuroendocrine/brain type alpha 1 subunit, Calcium channel voltage dependent L type alpha 1, Calcium channel voltage dependent L type alpha 1C subunit, Calcium channel voltage dependent L type alpha 1D subunit, Calcium channel voltage dependent L type alpha 1F subunit, Calcium channel voltage dependent alpha 1F subunit, Calcium channel, L type, alpha 1 polypeptide, isoform 3, skeletal, Calcium channel, L type, alpha 1 polypeptide, isoform 3, skeletal muscle, Calcium channel, L type, alpha 1 polypeptide, isoform 3, skeletal muscle, hypokalemic periodic paralysis, Calcium channel, skeletal muscle dihydropyridine sensitive , alpha 1 subunit, Calcium channel, voltage dependent, L type, alpha 1S subunit, Calcium channel, voltage-dependent, L type, alpha 1S subunit, b, Cardiac tetrodotoxin insensitive voltage dependent sodium channel alpha subunit, Cav1.1, Cav1.3, Cav1.4, Cav1.4alpha1, DHPR alpha 1, DHPR alpha 1 subunit, DHTR, Dihydro testosterone receptor, Dihydropyridine receptor, Dihydropyridine sensitive L type calcium channel alpha 1 subunit, Dihydrotestosterone receptor (DHTR), Drug-induced liver injury due to flucloxacillin, E3 ubiquitin ligase, E3 ubiquitin-protein ligase parkin, EIEE6, Eag-related protein 1, Ether a go go related potassium channel protein, Ether-a-go-go-related gene potassium channel 1, Ether-a-go-go-related protein 1, FEB3, FEB3A, FHM3, FLJ11090, FRA6E, Fibroblast interferon, G-protein coupled receptor 55, GEFS+2, GEFSP2, GPCR 2, GPCR GPR55, GPR55_HUMAN, H-ERG, HB 1, HB2, HBBD, HBSC I, HBSC II, HH1, HLA class I histocompatibility antigen, B-13 alpha chain, HLA class I histocompatibility antigen, B-14 alpha chain, HLA class I histocompatibility antigen, B-15 alpha chain, HLA class I histocompatibility antigen, B-18 alpha chain, HLA class I histocompatibility antigen, B-27 alpha chain, HLA class I histocompatibility antigen, B-35 alpha chain, HLA class I histocompatibility antigen, B-37 alpha chain, HLA class I histocompatibility antigen, B-38 alpha chain, HLA class I histocompatibility antigen, B-40 alpha chain, HLA class I histocompatibility antigen, B-41 alpha chain, HLA class I histocompatibility antigen, B-42 alpha chain, HLA class I histocompatibility antigen, B-44 alpha chain, HLA class I histocompatibility antigen, B-45 alpha chain, HLA class I histocompatibility antigen, B-46 alpha chain, HLA class I histocompatibility antigen, B-47 alpha chain, HLA class I histocompatibility antigen, B-48 alpha chain, HLA class I histocompatibility antigen, B-49 alpha chain, HLA class I histocompatibility antigen, B-50 alpha chain, HLA class I histocompatibility antigen, B-51 alpha chain, HLA class I histocompatibility antigen, B-52 alpha chain, HLA class I histocompatibility antigen, B-53 alpha chain, HLA class I histocompatibility antigen, B-54 alpha chain, HLA class I histocompatibility antigen, B-55 alpha chain, HLA class I histocompatibility antigen, B-56 alpha chain, HLA class I histocompatibility antigen, B-57 alpha chain, HLA class I histocompatibility antigen, B-58 alpha chain, HLA class I histocompatibility antigen, B-59 alpha chain, HLA class I histocompatibility antigen, B-67 alpha chain, HLA class I histocompatibility antigen, B-7 alpha chain, HLA class I histocompatibility antigen, B-73 alpha chain, HLA class I histocompatibility antigen, B-78 alpha chain, HLA class I histocompatibility antigen, B-8 alpha chain, HLA class I histocompatibility antigen, B-81 alpha chain, HLA class I histocompatibility antigen, B-82 alpha chain, HOKPP, HUMARA, HYSP1, HypoPP, ICCD, IFB, IFF, IFN-beta, IFNB 1, IFNB_HUMAN, IVF, Interferon beta, Interferon beta 1 fibroblast, Interferon beta precursor, JM 8, JMC 8, KCNH2_HUMAN, KD, KIAA1356, Kennedy disease (KD), Kv11.1, L type, LPIR1, LPRS 2, LQT 2, LQT3, LQT8, Lymphocyte antigen, MED, MGC104252, MGC112732, MGC96956, MHC class I antigen B 7, MHS5, Major Histocompatibility Complex Class I B, Malignant hyperthermia susceptibility 5, NAC3, NE NA, NR1I2_HUMAN, NR3C4, Nav 1.1, Neuroendocrine sodium channel, Nuclear receptor subfamily 1 group I member 2, Nuclear receptor subfamily 3 group C member 4, Nuclear receptor subfamily 3 group C member 4 (NR3C4), ONR 1, OTTHUMP00000215173, OTTHUMP00000215174, OTTHUMP00000215175, Orphan nuclear receptor PAR 1, Orphan nuclear receptor PXR, PAR, PAR q, PARK 2, PASNA, PDJ, PFHB1, PFIC 2, PGY4, PN 5, PN1, PN3, PRKN 2, PRKN2_HUMAN, PRR, Parkin 2, Parkinson disease (autosomal recessive juvenile) 2, Parkinson disease (autosomal recessive, juvenile) 2, parkin, Parkinson disease protein 2, Parkinson juvenile disease protein 2, Parkinson protein 2 E3 ubiquitin protein ligase, Parkinson protein 2, E3 ubiquitin protein ligase (parkin), Peripheral nerve sodium channel 3, Peripheral nerve sodium channel 5, Peripheral sodium channel 1, Potassium channel HERG, Potassium voltage gated channel subfamily H (eag related) member 2, Potassium voltage-gated channel subfamily H member 2, Pregnane X receptor, Probable G protein coupled receptor 55, RBI, ROB1, RP11 552M11.7, RP24-311F12.2, SANDD, SBMA, SCAN1, SCN 11A, SCN 12A, SCN1, SCN10A, SCN1A_HUMAN, SCN2A1, SCN2A2, SCN5A_HUMAN, SMAX1, SMEI, SNS 2, SQT1, SSS1, SXR, Scn5a (gene name), Sensory neuron sodium channel 2, Sister of P glycoprotein, SkM1, Sodium channel protein brain I alpha subunit, Sodium channel protein brain I subunit alpha, Sodium channel protein brain II subunit alpha, Sodium channel protein brain III subunit alpha, Sodium channel protein cardiac muscle alpha subunit, Sodium channel protein cardiac muscle subunit alpha, Sodium channel protein skeletal muscle subunit alpha, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha, Sodium channel protein type 11 subunit alpha, Sodium channel protein type 2 subunit alpha, Sodium channel protein type 3 subunit alpha, Sodium channel protein type 4 subunit alpha, Sodium channel protein type 5 subunit alpha, Sodium channel protein type 8 subunit alpha, Sodium channel protein type 9 subunit alpha, Sodium channel protein type I subunit alpha, Sodium channel protein type II subunit alpha, Sodium channel protein type III subunit alpha, Sodium channel protein type IV subunit alpha, Sodium channel protein type IX subunit alpha, Sodium channel protein type V alpha subunit, Sodium channel protein type V subunit alpha, Sodium channel protein type VIII subunit alpha, Sodium channel protein type X subunit alpha, Sodium channel protein type XI subunit alpha, Sodium channel voltage gated type 1 alpha subunit, Sodium channel voltage gated type I alpha polypeptide, Spgp, Spinal and bulbar muscular atrophy, Spinal and bulbar muscular atrophy (SBMA), Steroid and xenobiotic receptor, Synovitis, chronic, susceptibility to, TFM, TGPCR1, TRPA1_HUMAN, TS, TTPP1, TYDP, TYDP1_HUMAN, Testicular Feminization (TFM), Transformation-sensitive protein p120, Transient receptor potential cation channel subfamily A member 1, Tyr-DNA phosphodiesterase 1, Tyrosyl-DNA phosphodiesterase 1, Ubiquitin E3 ligase PRKN, VF1, Voltage dependent L type calcium channel alpha 1C subunit, Voltage ependent L ype calcium channel subunit alpha F, Voltage gated L type calcium channel Cav1.2 alpha 1 subunit, splice variant 10*, Voltage gated calcium channel alpha 1 subunit, Voltage gated calcium channel alpha 1F subunit, Voltage gated calcium channel alpha subunit Cav1.2, Voltage gated calcium channel alpha subunit Cav1.3, Voltage gated calcium channel subunit alpha Cav1.4, Voltage gated potassium channel, subfamily H, member 2, Voltage gated sodium channel alpha subunit Nav1.5, Voltage-dependent L-type calcium channel subunit alpha-1C, Voltage-dependent L-type calcium channel subunit alpha-1D, Voltage-dependent L-type calcium channel subunit alpha-1S, Voltage-gated calcium channel subunit alpha Cav1.1, Voltage-gated calcium channel subunit alpha Cav1.2, Voltage-gated calcium channel subunit alpha Cav1.3, Voltage-gated potassium channel subunit Kv11.1, Voltage-gated sodium channel subtype III, Voltage-gated sodium channel subunit alpha Nav1.1, Voltage-gated sodium channel subunit alpha Nav1.2, Voltage-gated sodium channel subunit alpha Nav1.3, Voltage-gated sodium channel subunit alpha Nav1.4, Voltage-gated sodium channel subunit alpha Nav1.5, Voltage-gated sodium channel subunit alpha Nav1.6, Voltage-gated sodium channel subunit alpha Nav1.7, Voltage-gated sodium channel subunit alpha Nav1.8, Voltage-gated sodium channel subunit alpha Nav1.9, alpha-1 polypeptide, androgen receptor splice variant 4b, bA552M11.5, brain sodium channel type I, cardiac muscle, eag homolog, fmd, hERG-1, hNE-Na, hNaN, hPN3, isoform 1, isoform 2, isoform 3, leukocyte antigen class I-B, pregnane X nuclear receptor variant 2, progressive familial intrahepatic cholestasis 2, sj
Recommended products
MW 360.4 Da, Purity >98%. L-type Ca2+ channel blocker. Antihypertensive *in vivo*. Achieve your results faster with highly validated, pure and trusted compounds.
Key facts
- CAS number
- 39562-70-4
- Purity
- > 98%
- Form
- Solid
- Molecular weight
- 360.4 Da
- Molecular formula
- C18H20N2O6
- PubChem identifier
- 4507
- Nature
- Synthetic
- Solubility
Soluble in DMSO to 50 mM.
Soluble in ethanol to 25 mM.
- Biochemical name
- Nitrendipine
- Biological description
L-type Ca2+ channel blocker. Antihypertensive *in vivo*.
- Canonical SMILES
- CCOC(=O)C1=C(NC(=C(C1C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC)C)C
- InChI
- InChI=1S/C18H20N2O6/c1-5-26-18(22)15-11(3)19-10(2)14(17(21)25-4)16(15)12-7-6-8-13(9-12)20(23)24/h6-9,16,19H,5H2,1-4H3
- InChIKey
- PVHUJELLJLJGLN-UHFFFAOYSA-N
- IUPAC name
- 5-O-ethyl 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Storage
- Shipped at conditions
- Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
- Ambient
- Appropriate long-term storage conditions
- Ambient
- Storage information
- The product can be stored for up to 12 months
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
Parkin also known as PRKN functions as an E3 ubiquitin-protein ligase involved in the ubiquitination and degradation of proteins. It has a mass of approximately 52 kDa and is expressed mainly in the brain heart and muscle tissues. The gene encoding for this protein is located on chromosome 6q25.2-q27. Interferon beta CACNA1C TDP1 and Androgen Receptor are integral to cellular processes with expressions in various tissues. CACNA1C constitutes a vital part of the voltage-gated calcium channel while the Androgen Receptor acts in signal transduction for hormones. These targets contribute to modulating cellular functions and responses.
- Biological function summary
Parkin is essential in maintaining cellular homeostasis and stress response through its role in the ubiquitin-proteasome system. It forms a complex with PINK1 facilitating the clearance of damaged mitochondria. CACNA1C is part of the L-type calcium channel complex playing a role in cardiac and smooth muscle contraction. TDP1 assists in DNA repair processes. The Androgen Receptor modulates the expression of genes related to cellular proliferation. Other targets like PXR TRPA1 and GPCR GPR55 mediate cellular responses to various stimuli impacting metabolic and sensory pathways.
- Pathways
Parkin integrates into the mitophagy pathway and is associated with PINK1 to regulate mitochondrial quality. CACNA1C participates in calcium signaling pathways influencing cardiac action potentials. Androgen Receptor links with the androgen signaling pathway impacting reproductive tissue function. PXR interacts with drug metabolism pathways affecting the detoxification of xenobiotics. Adenosine A3 Receptor and HLA B7 involve immune response modulation whereas SCN1a and Nav1.5/SCN5A influence the sodium channel pathways critical for neuronal and cardiac function.
- Associated diseases and disorders
Parkin mutations associate with Parkinson's disease linking it to dopaminergic neuron degradation. CACNA1C mutations correlate with Timothy syndrome affecting calcium signaling and cardiac rhythm. Androgen Receptor abnormalities connect to prostate cancer playing a role in tumor growth through hormone regulation. Mutations in SCN1a relate to epilepsy influencing neuronal excitability. H-ERG mutations lead to Long QT syndrome affecting cardiac rhythm. These proteins interact with various signaling molecules in disease pathogenesis highlighting their clinical relevance.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2 product images
Chemical Structure - Nitrendipine, L-type Ca2+ channel blocker (ab120139)
2D chemical structure image of ab120139, Nitrendipine, L-type Ca2+ channel blocker
Functional Studies - Nitrendipine, L-type Ca2+ channel blocker (ab120139)
ab2770 staining aryl hydrocarbon receptor in MDA-MB-231 cells treated with nitrendipine (ab120139), by ICC/IF. Increase in aryl hydrocarbon receptor expression correlates with increased concentration of nitrendipine, as described in literature.
The cells were incubated at 37°C for 6h in media containing different concentrations of ab120139 (nitrendipine) in DMSO, fixed with 100% methanol for 5 minutes at -20°C and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab2770 (1/100 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-mouse polyclonal antibody (Goat Anti-Mouse IgG H&L (DyLight® 488) preadsorbed ab96879) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com